Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine,
Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
A Pittsburgh native, Dr. Liu graduated cum laude at Johns Hopkins University with a major in Biology and a minor in Film and Media Studies, before receiving his M.D. at the University of Maryland. He completed his Internal Medicine training at the University of Pennsylvania and a dual fellowship in Hematology and Oncology at the University of Southern California, after which he received further specialized training in genomic medicine at the Translational Genomics Research Institute (TGen) under Dr. Daniel Von Hoff. Dr. Liu has been part of the Thoracic Oncology section and the Experimental Therapeutics Program of Georgetown University since 2013. He is a board-certified medical oncologist with expertise in thoracic malignancies including lung cancer, thymic malignancies, and mesothelioma.
Dr. Liu has a research focus on the development of novel therapeutic agents and innovative combinations for the treatment of advanced thoracic malignancies. He leads the Thoracic Oncology section and the Phase I Developmental Therapeutics group. His work has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lancet Oncology, Cancer Discovery, and Clinical Cancer Research. He is actively involved in post-graduate education and has been awarded multiple teaching awards for his efforts. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr. Liu has also served as the Chief Editor for Frontiers in Thoracic Oncology since 2014.
Dr. Liu's Philosophy of Care:
I subscribe to MedStar Georgetown University Hospital's mission - cura personalis - caring for the whole person and I am an advocate for my patients. I stress the importance of open communication between physicians and patients and strive to provide my patients with the most advanced care available. I strongly believe that all patients deserve the opportunity to benefit from the latest cancer research advances, including genomic testing which is becoming increasingly important to identify differences between patients' cancers and guide treatment decisions. I am also committed to conducting research that will contribute to our understanding of cancer and helping future patients.